Sponsor Pipeline

Hebei Senlang Biotechnology Inc., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
9
Active Trials
6
Recruiting
3
Disease Areas
Active Trials by Phase
Phase 2
2
Phase 1/2
2
Phase 1
2
Early Phase 1
1
Not specified
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07244406 Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL B-ALL Recruiting
NCT07244380 Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. T Lymphoblastic Leukemia/Lymphoma Not Yet Recruiting
Phase 1/2
NCT07161193 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases Autoimmune Diseases Not Yet Recruiting
NCT07421856 Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter… Multiple Myeloma in Relapse Not Yet Recruiting
Phase 1
NCT06136364 CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study T-lymphoblastic Lymphoma Recruiting
NCT05388695 To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell… 19 and 22+ B Cell Hematologic Tumors Recruiting
Early Phase 1
NCT07435779 Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A… UC Recruiting
Not specified
NCT05626400 Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+… T-cell Acute Lymphoblastic Leukemia/Lymphoma Recruiting
NCT05618041 The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With… Acute Lymphoblastic Leukemia Recruiting
Disease Areas
Get alerts when Hebei Senlang Biotechnology Inc., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free